Finn Gustav Bengtsson, born 4 June 1956, is a Swedish politician (moderate), who is a Member of Parliament since 2006. During the term of 2006-2010 he served as Deputy Governor of Gunilla Carlsson. During that term, he was an alternate member of the Social Committee, the Social Insurance Committee and the Board of the Foundation of the Riksbank's Jubilee Fund. During the following mandate period 2010-2014, Bengtsson was a member of the Social Insurance Committee and the Board of Directors of the Foundation, the Riksbank's Jubilee Fund and alternate member of the Finance Committee. The term 2014-2018 is Bengtsson member of the Social Committee. He is elected for the county of Östergötland. Bengtsson is a senior physician and professor of clinical pharmacology.

Pharmacology

Dr. Tirotta has been an active member of Miami Children’s Hospital medical staff since 1991, practicing with the Department of Anesthesiology; he has served as the Director of Cardiac Anesthesia since 2002. He has served as Chief of the Department of Anesthesia since July 2017. He also has a clinical appointment with the Department of Anesthesiology at The University of Miami School of Medicine Dr. Tirotta received his BA from Cornell University in 1982 and his MD from New York University School of Medicine in 1986. He also received an MBA degree from Columbia University in 1999. Dr. Tirotta completed his internship in Internal Medicine at SUNY at Stony Brook in 1987. He completed his residency training in anesthesiology at the University of Miami/Jackson Memorial Hospital in 1990; he subspecialized in pediatric and cardiovascular anesthesia, including heart transplantation. In 1994, Dr. Tirotta created and produced the widely acclaimed pre-operative educational video titled, “A Hospital Trip with Dr. Bip”. This program, narrated by the endearing animated character Dr. Bip, explains to young children what to expect when they go to the hospital for surgery. It also includes coloring books and stickers. This program was exhibited at numerous national medical conventions and has sold thousands of copies all over the English-speaking world. Dr. Tirotta is a member of numerous professional societies and has served on a number of hospital committees, including the Heart Program Executive Committee. He previously served as the Co-Chair of the Miami Children’s Hospital Physician Hospital Organization. He is also responsible for giving numerous medical lectures nationally and internationally and is actively engaged in clinical research. He has been the Principal Investigator on a number of clinical drug/device trials, including on the ONQ Pain Buster, the muscle relaxant Zemuron, the procoagulant RiaSTAP, the Cardiotronic NICOM device and the ClearLine. He will also be the Principal Investiagator in Merck’s Sugammadex pediatric trial and Pacira Pharmaceuticals pediatric Exparel trial.

clinical drug/device trials, pediatric surgery, pharmaceuticals

Dr. Joseph L. Borowitz served as a Professor of Pharmacology at the Purdue University. His research work revolved around neurotoxicity of cyanide. He completed his bachelors of science in the year of 1955 from Ohio State University. He obtained his masters of science from the Purdue University in the year of 1957. He have recieved his Ph.D. in the year of 1959 from the Northwestern University. Dr. Borowitz is currently serving as a Professor Emeritus of Pharmacology at the Purdue University.

Neurotoxicity, Toxicology

Prof. Karen Mulkijanyan heads the Department of Preclinical Pharmacological Research at Tbilisi State Medical University Institute of Pharmacochemistry. He holds MS in Biochemistry and PhD in Pharmacy. K.Mulkijanyan’s research areas are: pharmacology of anti-inflammatory and wound healing drugs; analysis of SAR and prediction of bioactivity of natural, modified and synthesized compounds; technology transfer and commercialization; laboratory animal science. He authored and co-authored over 120 peer-reviewed publications, 40 presentations at international scientific meetings, 2 patents, and is editorial board member of several journals. Since 2015 Prof. Mulkijanyan is the president of Georgian Association for Laboratory Animal Science.

Pharmacology of anti-inflammatory, ulcer preventive, wound healing drugs; analysis of structure-activity relationship (SAR) and prediction of bioactivity of natural, modified and synthesized compounds; intellectual property protection; technology transfer and technology commercialization, use and care of laboratory animals.

JAMES M. CREGG is awarded PhD in Life Sciences from Rice University, Houston, Texas in the year 1978. He holds a Master Degree in Biology from Rice University, Houston, Texas in the year 1975, followed by a Bachelor’s Degree in Western Maryland College, Westminster, Maryland in the year 1972. He has extended his valuable service in Keck Graduate Institute of Applied Life Sciences, Claremont, California for 14 years and has been a recipient of many award and grants. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals. He is the Editorial Board Member of Protein Expression and Purification, 1999-present and serves as a member of various associations American Association for the Advancement of Science, American Society for Microbiology, American Society for Cell Biology.

Production of recombinant proteins for medical and industrial uses

Joel Richard has got a PhD in Materials Science (University of Paris VI, 1987). He is Senior Vice President for Peptides Development in Ipsen. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, sustained-release formulations etc.). He is the author of more than 120 international communications and 53 patent families

colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, sustained-release formulations

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

antihyperglycemics and their study, Endocrine Pharmacology

Jan Olof G. Karlsson has a PhD in pharmacology from Linköping University, Sweden, where he also holds a position as an assistant professor. Between 1990 and 1992 he held a position as a research fellow at the Swedish Medical Research Council. Thereafter he was offered a position as a senior research scientist at Nycomed Imaging AS in Oslo (which later became GE Healthcare), where he stayed until 2007. Karlsson is one of the founders of PledPharma AB, where he worked between 2007 and 2014. This company is developing MnPLED-derivatives as new medicinal products intended for treatment of serious diseases, such as cancer and acetaminophen intoxication. He has successfully supervised three PhD students and number of students during their Master works. Karlsson has published 76 scientific papers and is inventor of 9 issued patent families including the new chemical entity calmangafodipir (PledOx®).

Superoxide dismutase mimetic activity and heavy metal binding capability of MnPLED-derivatives - potentially useful properties in treatment of variety of pathological conditions.

Jan Olof G. Karlsson has a PhD in pharmacology from Linköping University, Sweden, where he also became an assistant professor of pharmacology in 1991. Between 1990 and 1992 he held a position as a research fellow at the Swedish Medical Research Council. Thereafter he was offered a position as a senior research scientist at Nycomed Imaging AS in Oslo. He was a member of the Visipaque project that developed an x-ray contrast agent that is one of the absolute best selling contrast agents today. Karlsson worked for Nycomed Imaging, which later became GE Healthcare, until 2007. He has successfully supervised three PhD students and number of students during their Master works. Karlsson has published more than 70 scientific papers. Among his original discoveries, one can mention his discovery that photorelaxation is mediated by cGMP and that MnPLED-derivatives possess SOD-mimetic activity. Karlsson is inventor on nine issued patent families and on three additional patent applications. Of these ten applications, he is the main inventor on six of them. During the early 1990’s Karlsson was involved in research showing that the MRI contrast agent mangafodipir and other MnPLED-derivatives possess SOD-mimetic activity, a potentially useful property in treatment of variety of pathological conditions. Karlsson is a member of the Senior Editorial Board of the American Journal of Cancer Therapy and Pharmacology. He is also a member of the Scientific Advisory Board of Spago Imaging AB.

Cancer Therapy and Pharmacology